Evidence map›Paper›PMID 38769551›Full record

ArticleJournal of nanobiotechnology2024

Chondroitin sulfate-modified tragacanth gum-gelatin composite nanocapsules loaded with curcumin nanocrystals for the treatment of arthritis.

Junpeng Sun, Jiaqun Du, Xiaobang Liu, Jinyu An, Yu Hu, Jing Wang, Fu Zhu, Huicong Feng, Shuai Cheng, He Tian and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Advances in the use of nanotechnology for treating gout.Nanomedicine (London, England) · 2025
    Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Junpeng SunPharmacy School, Jinzhou Medical University, Jinzhou, Liaoning, 121001, China.
Jiaqun DuPharmacy School, Jinzhou Medical University, Jinzhou, Liaoning, 121001, China.
Xiaobang LiuPharmacy School, Jinzhou Medical University, Jinzhou, Liaoning, 121001, China.
Jinyu AnPharmacy School, Jinzhou Medical University, Jinzhou, Liaoning, 121001, China.
Yu HuLiaoning Provincial Collaborative Innovation Center of Medical Testing and Drug Development, Jinzhou Medical University, Jinzhou, Liaoning, 121001, China.
Jing WangPharmacy School, Jinzhou Medical University, Jinzhou, Liaoning, 121001, China.
Fu ZhuPharmacy School, Jinzhou Medical University, Jinzhou, Liaoning, 121001, China.
Huicong FengLiaoning Provincial Collaborative Innovation Center of Medical Testing and Drug Development, Jinzhou Medical University, Jinzhou, Liaoning, 121001, China.
Shuai ChengLiaoning Provincial Collaborative Innovation Center of Medical Testing and Drug Development, Jinzhou Medical University, Jinzhou, Liaoning, 121001, China.
He TianLiaoning Provincial Collaborative Innovation Center of Medical Testing and Drug Development, Jinzhou Medical University, Jinzhou, Liaoning, 121001, China. tianhe@jzmu.edu.cn.
Xifan MeiLiaoning Provincial Collaborative Innovation Center of Medical Testing and Drug Development, Jinzhou Medical University, Jinzhou, Liaoning, 121001, China. meixifan@jzmu.edu.cn.
Chao WuPharmacy School, Jinzhou Medical University, Jinzhou, Liaoning, 121001, China. wuchao@jzmu.edu.cn.

Funding

Application Research Project of Jinzhou Medical University H2021024Liaoning Province Applied Basic Research Program Joint Project 2023021109-JH2/1017Liaoning Provincial Key Laboratory of Marine Bioactive Substances and Technological Innovation Center of Liaoning Pharmaceutical Action and Quality Evaluation 2022-8Natural Science Foundation of Liaoning Province 2022-MS-390Scientific and technological projects of Jinzhou city JZ2022B042Scientific Research Project of the Educational Department of Liaoning Province JYTJCZR202007
6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune disease of yet undetermined etiology that is accompanied by significant oxidative stress, inflammatory responses,  and damage to joint tissues. In this study, we designed chondroitin sulfate (CS)-modified tragacanth gum-gelatin composite nanocapsules (CS-Cur-TGNCs) loaded with curcumin nanocrystals (Cur-NCs), which rely on the ability of CS to target CD44 to accumulate drugs in inflamed joints. Cur was encapsulated in the form of nanocrystals into tragacanth gum-gelatin composite nanocapsules (TGNCs) by using an inborn microcrystallization method, which produced CS-Cur-TGNCs with a particle size of approximately 80 ± 11.54 nm and a drug loading capacity of 54.18 ± 5.17%. In an in vitro drug release assay, CS-Cur-TGNCs showed MMP-2-responsive properties. During the treatment of RA, CS-Cur-TGNCs significantly inhibited oxidative stress, promoted the polarization of M2-type macrophages to M1-type macrophages, and decreased the expression of inflammatory factors (TNF-α, IL-1β, and IL-6). In addition, it also exerted excellent anti-inflammatory effects, and significantly alleviated the swelling of joints during the treatment of gouty arthritis (GA). Therefore, CS-Cur-TGNCs, as a novel drug delivery system, could lead to new ideas for clinical therapeutic regimens for RA and GA.

Indexed as

Chondroitin SulfatesCurcuminGelatinNanocapsulesNanoparticlesTragacanthAnimalsAnti-Inflammatory AgentsArthritis, RheumatoidDrug LiberationMacrophagesMaleMiceOxidative StressParticle SizeRatsAnti-Inflammatory AgentsChondroitin SulfatesCurcuminGelatinNanocapsulesTragacanthCurcuminGelatinGouty arthritisRheumatoid arthritisTragacanth gum

Identifiers

PMID38769551
PMCPMC11104008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.